Related Experiment Video
Updated: Feb 28, 2026
05:51
Characterization of a Novel Human Organotypic Retinal Culture Technique
Published on: June 9, 2021
4.7K
Correlation between Interleukin-6 and Thrombin-Antithrombin III Complex Levels in Retinal Diseases
Rita Ehrlich1,2, Alon Zahavi1,2, Ruth Axer-Siegel1,2
1a Department of Ophthalmology , Rabin Medical Center , Petach Tikva , Israel.
Current Eye Research
|June 21, 2017
Summary
Vitreous levels of interleukin-6 (IL-6) and thrombin-antithrombin III complex (TAT) differ significantly across various vitreoretinal pathologies. These findings suggest intraocular tissue influences thrombin regulation in ocular diseases.
Area of Science:
- Ophthalmology
- Biochemistry
- Immunology
Background:
- Vitreous biomarkers like IL-6 and TAT are crucial for understanding ocular disease mechanisms.
- Previous research has explored these markers individually, but their correlation in diverse vitreoretinal pathologies requires further investigation.
Purpose of the Study:
- To evaluate and correlate vitreous levels of interleukin-6 (IL-6) and thrombin-antithrombin III complex (TAT) in patients with macular hole/epiretinal membrane, rhegmatogenous retinal detachment, and proliferative diabetic retinopathy.
- To explore potential differences in IL-6 and TAT levels based on specific vitreoretinal pathologies.
Main Methods:
- Vitreous samples were obtained from 78 patients undergoing pars plana vitrectomy.
- Patients were categorized into three groups: macular hole/epiretinal membrane (MH/ERM), rhegmatogenous retinal detachment (RRD), and proliferative diabetic retinopathy (PDR).
- Enzyme-linked immunosorbent assay (ELISA) was used to measure IL-6 and TAT levels, followed by comparative analysis among groups.
Main Results:
- Significant differences in vitreous IL-6 and TAT levels were observed between the MH/ERM group and both the PDR and RRD groups (P < 0.001).
- Higher IL-6 levels were associated with RRD in diabetic patients.
- Distinct correlations between IL-6 and TAT levels were identified across different ocular pathologies.
Conclusions:
- Vitreous IL-6 and TAT levels serve as important indicators that vary with specific vitreoretinal diseases.
- The observed differences suggest that intraocular tissue-dependent regulation of thrombin plays a role, in addition to inflammation and blood-retinal barrier breakdown.
- Further research into these biomarkers may offer insights into disease pathogenesis and potential therapeutic targets.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
399
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
399
01:29Venous Thrombosis III: Interprofessional Care
423
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
423
01:20Drug Product Performance: In Vitro–In Vivo Correlation
326
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
326